Search results | CSL


Partnering Agreements with CSL

This report provides all the information you require to better understand CSL and its partnering interests and activities over the past seven years.



CSL is a top pharmaceutical company based in Melbourne, Australia

CSL: Protecting patients globally with vaccines and plasma products

CSL is a large speciality biopharmaceutical company developing and manufacturing plasma products and vaccines to treat and protect patients worldwide.

CSL M&A deals 2005-2013

CSL has announced only 1 M&A deal since 2005, with the acquisition of Zenyth Therapeutics

CSL: Partnering activity 2005-2013

CSL is a global pharma company active in the development of vaccines and plasma proteins with a prime focus on influenza vaccine – partnering, collaborative R&D and licensing activity of CSL is reviewed here.

CSL: Company profile

CSL, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Current Agreements Deal Analysis Update : November 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in October 2014.

Current Agreements Deals Update : January 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in December 2013

Xenome, once heralded as a star for Queensland’s biotechnology industry, suffers major setback

Dealtalk: Plans to develop Xenome’s molecule, derived from shellfish venom, to soothe acute post-surgery pain, have been shipwrecked.

Biopharma features strongly in 2013 world’s most innovative companies list

Partnering activity of the biopharma companies in Forbes Most Innovative Company list reviewed

Leader in plasma protein therapies created through Grifols/Talecris combination

It is a rare event to see a multi-billion dollar acquisition take place involving a company outside the bigpharma top 50.


Sorry, your search returned no results.


CSL has acquired the Flu vaccine business from Novartis

Novartis announced has entered an agreement that CSL has acquired its influenza vaccine business in a $275 million deal that will require regulatory approval before it closes by the end of the second half of 2015.

$950m share buy back for blood specialist CSL

Vaccine maker and blood products specialist CSL in $950m share buyback.

CSL Biotherapies makes pharma news with $1.5 billion award from US Government

A popular headlines on the pharma news was CSL Biotherapies award of $1.5billion from the United States Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile .

Merck inks domestic rights to Afluria from CSL

The six-year agreement with CSL Biotherapies, a division of CSL, calls for Merck to market Afluria in the United States, where it was approved by the Food and Drug Administration in 2007, starting next year. CSL will make the vaccine and maintain marketing and distribution rights in the rest of the world.

Merck obtains exclusive US marketing rights for AFLURIA from CSL Biotherapies

Merck will assume responsibility for all aspects of commercialization of AFLURIA in the U.S. CSL will supply AFLURIA to Merck and will retain responsibility for marketing the vaccine outside the U.S. Specific financial details of the agreement were not disclosed.

Castlight Health prices its IPO financing

Castlight Health is to raise $176 million in IPO financing.